Claude Nicaise
Known title: DirectorCIK: 0001644162
Associated companies
Transaction History
| SRPT | ▲ Buy | Grant | 16,875 | — | 6/4/2026 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 10,500 | $144K | 1/29/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 6,780 | $144K | 1/29/2026 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 9,746 | $245K | 3/12/2025 | View on chart |
| SRPT | ▼ Sell | Open Market | 2,491 | $248K | 3/12/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 2,383 | — | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 1,846 | $0 | 3/1/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 1,523 | $0 | 3/6/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 2,953 | $0 | 3/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Sarepta Shares New DM1 Data at Oligonucleotide Meeting
Sarepta Therapeutics presented new preclinical data for SRP-1003, a treatment for myotonic dystrophy type 1, at the 2026 Oligonucleotide Therapeutics Society Annual Meeting. The data indicated robust knockdown of pathogenic DMPK RNA in the nucleus. This update highlights the company's ongoing research efforts, while the stock currently trades near its 52-week low with a volume spike.
Sarepta Shares New DM1 Data at Oligonucleotide Meeting. Sarepta Therapeutics presented new preclinical data for SRP-1003, a treatment for myotonic dystrophy type 1, at the 2026 Oligonucleotide Therapeutics Society Annual Meeting. The data indicated robust knockdown of pathogenic DMPK RNA in the nucleus. This update highlights the company's ongoing research efforts, while the stock currently trades near its 52-week low with a volume spike.